Ipamorelin
Selective GH secretagogue; Still not a benign wellness shortcut
Brief Overview: Ipamorelin is a ghrelin-receptor agonist used to stimulate GH release with less cortisol and prolactin spillover than older GHRPs. Evidence lens: It is cleaner than GHRP-2/GHRP-6 pharmacologically, but not FDA-approved for broad wellness use. Body-composition and recovery claims still need evidence. How to read this: if you're new, focus on the GH pulse concept. Once you're past the basics, track IGF-1, glucose, edema, sleep apnea symptoms, and desensitization rather than assuming more is better.
- A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and selective agonist of the ghrelin receptor (GHS-R1a).
- Developed in the late 1990s by Novo Nordisk as a third-generation growth-hormone-releasing peptide (GHRP).
- Known as the “cleanest” GHRP: it has the highest selectivity for growth-hormone release, without the cross-reactivity seen in earlier GHRPs.
- Ipamorelin is a selective ghrelin/GHS-R agonist GH secretagogue. It is distinct from GHRP-2/GHRP-6/hexarelin because its appeal is lower cortisol/prolactin spillover, not simply stronger GH release.
- Selective GH release: triggers a GH pulse at the ghrelin receptor but, unlike GHRP-2 or GHRP-6, does not meaningfully raise ACTH, cortisol, or prolactin even at higher doses.
- Preserved pulsatility: it enhances the body's natural pulsatile GH pattern rather than forcing a constant, unphysiological release.
- Somatostatin inhibition: suppresses the body's main GH off-switch, letting the natural GHRH signal work more effectively.
- Secondary IGF-1 rise: downstream liver IGF-1 increases and drives systemic repair. IGF-1 is the usual marker but not a complete safety or efficacy endpoint.
- It stimulates GH pulses through GHS-R while generally being described as more selective in endocrine spillover. Pituitary reserve, sleep, nutrition, and age influence response. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Sleep architecture: noted for increasing slow-wave (deep) sleep, the main window for physiological repair.
- Bone mineral density: recent data suggests it stimulates osteoblast activity, a focus for age-related bone-loss research.
- Gut motility: originally studied for post-operative ileus, with trials exploring restart of gut motility without the hunger spikes of older ghrelin mimetics.
- Muscle preservation: anti-catabolic properties may preserve lean mass during stress or caloric restriction without disrupting blood glucose.
- Caveat: clinical applications remain largely investigational; Common anti-aging or recovery claims are not equivalent to approved therapy.
- Human endocrine evidence supports GH release, but body-composition, anti-aging, and recovery outcomes are not proven at community-protocol level. The evidence is better for mechanism than outcomes. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Anti-Aging / Wellness [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 100 mcg – 200 mcg; Frequency: Once Daily (at Night); Timing: Fasted (Before Bed); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Performance / Recovery [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 200 mcg – 300 mcg; Frequency: 2 to 3 Times Daily; Timing: Fasted (Morning/Pre-workout); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Often paired with CJC/no-DAC or sermorelin in pulse-style evening protocols. 5-on/2-off is common but not proven necessary for once-nightly short-acting exposure. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: about 10 hours.
- Half-life basis: human PK/PD modeling reports a terminal half-life of roughly 2 hours. The relevant effect is a GH pulse, not a constant exposure target.
- Beginner translation: A 10-hour steady-state estimate does not mean the GH pulse lasts 10 hours. The endocrine response rises and falls around each exposure.
- Practical interpretation: Monitor IGF-1, fasting glucose, edema, sleep quality, and symptoms; Do not use constant exposure as the goal.
- Comparison note: Ipamorelin is usually framed as cleaner than GHRP-2 and GHRP-6, with less hunger and less cortisol/prolactin spillover. It is still a hormone-axis drug and still carries risk.
- Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
- Short exposure supports pulse logic. However, IGF-1 and tissue effects are downstream, so half-life alone cannot predict benefit or risk. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- The classic pairing is with CJC-1295 without DAC or sermorelin to mimic the GHRH plus ghrelin dual signal. Stacking with tesamorelin or other GH-axis agents should be clinician-guided because side effects overlap.
- The common CJC/ipamorelin stack is mechanistically coherent but is not automatically safe or same-vial compatible. Additive GH-axis exposure needs monitoring. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Potential issues include water retention, headache, numbness/tingling, injection-site irritation, glucose worsening, sleep apnea worsening, and theoretical risk in active malignancy.
- Lower prolactin/cortisol spillover does not mean no risk.
- Watch edema, tingling, appetite change, sleep apnea, glucose changes, headache, and injection reactions. Risk rises with high IGF-1 or stacking with other GH-axis agents. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Monitor IGF-1, fasting glucose, HbA1c, edema, blood pressure, sleep apnea symptoms, and symptom response.
- Body composition and recovery metrics are more meaningful than subjective “GH feeling.”
- Track IGF-1, fasting glucose/A1c, sleep quality, edema, blood pressure, carpal-tunnel symptoms, weight/waist, and subjective recovery with training load noted. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: not approved; Classified as investigational. It was removed from the Category 2 do-not-compound list in September 2024 after nominators withdrew, and on February 27, 2026 HHS named it among roughly 14 peptides expected to return to Category 1 for legal compounding access.
- Still under review: expected to be referred to a future Pharmacy Compounding Advisory Committee meeting; Not approved for any indication.
- WADA: banned under S2 (peptide hormones and growth factors) and detectable in urine and blood for several days after a dose.
- Availability: widely compounded in wellness practice; Verify current status with the pharmacy.
- Ipamorelin is not FDA-approved for wellness/body composition. FDA has flagged compounded ipamorelin safety and characterization concerns. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.